Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients

https://doi.org/10.1016/0049-0172(89)90085-1Get rights and content

Abstract

The significance of hepatic changes in methotrexate-treated RA patients is unclear at this time.36 In our group of RA patients, there was a slight increase in the incidence of triaditis and fat during methotrexate therapy. Disease duration ≥ 10 years was associated with increased hepatic triaditis before treatment. Age > 50 years was associated with increased hepatic fat before and after treatment. It appears that patients' ages and duration of underlying RA account for some changes, independent of methotrexate therapy. Several of our patients changed from higher to lower histologic grade or had an apparent decrease in fibrosis, fat, or triaditis on the pathologists' reports and the blind readings of the repeat biopsies. This may be explained by sampling error. More importantly, some of these changes may not be of clinical significance. One report of methotrexate-induced cirrhosis in patients with psoriasis demonstrated that in all but one of 14 patients who continued receiving methotrexate the cirrhosis decreased or did not progress.47 This may also be true of the hepatic fibrosis seen in RA after methotrexate treatment.64,65

In this study, there did not appear to be changes seen on pretreatment liver biopsy that were predictive of subsequent fibrosis or cirrhosis. Our data indicate that pretreatment biopsy is unwarranted in a population similar to ours. However, our practice has been to try to avoid methotrexate in patients with diabetes, prior liver disease, alcoholism, or obesity because of previous reports suggesting that these patients are at increased risk for the development of cirrhosis.29 Only the above-mentioned patient, eventually diagnosed as having cirrhosis, might have been handled differently.

Including this study, none of the approximately 700 RA patients in the literature having liver biopsies after methotrexate therapy have developed cirrhosis consequent to its use. Most of these had received a total dose of approximately 1,500 mg in small weekly doses, and alcohol was prohibited. Below this cumulative dose the risk of clinically significant liver damage in carefully selected patients is very low. In view of this experience, the recommendation that RA patients have liver biopsies after 1,500 mg of methotrexate68 (a holdover from the psoriasis literature) may be too conservative in low-risk RA patients, provided methotrexate is administered weekly and alcohol is prohibited. Recognizing that the absolute need for biopsy is unproven, a more realistic milestone for those choosing biopsy might be after each 2,000 to 2,500 mg. Until more data are available this will need to be a decision arrived at by the physician and patient.

Obviously, a longer period of observation will be needed to confirm these conclusions regarding the hepatic abnormalities in RA patients following methotrexate treatment. This is particularly true of the portal fibrosis or portal tract expansion seen in these biopsies even before methotrexate treatment, because the natural history of these changes is not clear. It is important to emphasize that our data do not exclude the possibility that at higher cumulative doses or after longer duration of therapy, clinically significant liver problems may become manifest in these patients. More data are desperately needed from RA patients treated with > 5 g of methotrexate and should be available within the next few years. However, the results of this study are encouraging and suggest that cautious optimism is in order regarding the short- and intermediateterm hepatic effects of this drug in RA patients failing or intolerant of more conventional therapy.

References (68)

  • CH Adams et al.

    Gold therapy in early rheumatoid arthritis

    Ann Intern Med

    (1950)
  • JR Ward et al.

    Comparison of auranofin, gold sodium thiomalate and placebo in treatment of rheumatoid arthritis

    Arthritis Rheum

    (1983)
  • PN Sambrook et al.

    Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis

    J Rheumatol

    (1982)
  • JA Richter et al.

    Analysis of treatment terminations with gold and anti-malarial compounds in rheumatoid arthritis

    J Rheumatol

    (1980)
  • R Gubner et al.

    Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis

    Am J Med Sci

    (1951)
  • The Cooperating Clinics Committee of the ARA

    A controlled trial of gold salt therapy in rheumatoid arthritis

    Arthritis Rheum

    (1973)
  • HF Polley et al.

    Behind the scenes with cortisone and ACTH

  • WM O'Brien

    Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis

    B J Clin Pharmacol

    (1986)
  • CJ Smyth et al.

    Cyclophosphamide therapy for rheumatoid arthritis

    Arch Intern Med

    (1975)
  • GL Baker et al.

    Malignancy in cyclophosphamide-treated rheumatoid arthritis patients: A long-term followup study

    Clin Res

    (1985)
  • RR Reimer et al.

    Acute leukemia after alkylating-agent therapy of ovarian cancer

    N Engl J Med

    (1977)
  • JL Decker

    Toxicity of immunosuppressive drugs in man

    Arthritis Rheum

    (1973)
  • RF Willkens et al.

    Methotrexate: A perspective of its use in the treatment of rheumatic diseases

    J Lab Clin Med

    (1982)
  • Health and Public Policy Committee et al.

    Methotrexate in rheumatoid arthritis

    Ann Intern Med

    (1987)
  • N Erikson et al.

    Significant methotrexate (MTX) toxicity in RA patients. Results of an ongoing long-term prospective trial

    Arthritis Rheum

    (1987)
  • JG Gispen et al.

    Toxicities to methotrexate in rheumatoid arthritis

    J Rheumatol

    (1987)
  • H Hamdy et al.

    Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis

    Arthritis Rheum

    (1987)
  • R Rau et al.

    Retardation of radiographic progression in rheumatoid arthritis (RA) with methotrexate

    Arthritis Rheum

    (1988)
  • NR Straniero et al.

    Case-control study of progression of hand x-ray changes in RA patients taking methotrexate(MTX), NSAIDS, gold or other remittive agents

    Arthritis Rheum

    (1988)
  • MW Ropes et al.

    1958 revision of diagnostic criteria for rheumatoid arthritis

    Bull Rheum Dis

    (1978)
  • DM GallantDM Gallant
  • HH Roenigk et al.

    Methotrexate guidelines—Revised

    J Am Acad Dermatol

    (1982)
  • RC Duncan et al.

    Introductory Biostatistics for the Health Sciences

  • JE Brick et al.

    Outcome analysis of selected methotrexate (MTX) treated rheumatoid arthritis (RA) patients

    Arthritis Rheum

    (1988)
  • Cited by (68)

    • Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study

      2017, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      Gastrointestinal toxicities are most frequent, with a prevalence of 20–65%, and are usually characterized by mild or moderate severity (e.g., nausea, vomiting, diarrhea, and abdominal pain) [13,16–19]. Liver toxicity is a common concern and up to 20% of LDM users are estimated to have at least one episode of elevated serum transaminases, and 3.7% discontinue LDM due to liver toxicity [13,20–26]. Interstitial pneumonitis represents the most serious respiratory toxicity for LDM, presenting as an acute hypersensitivity reaction with cough, fever, and subacute dyspnea, with mortality rates estimated up to 17% [27,28].

    • Vascular disorders

      2012, MacSween's Pathology of the Liver
    • Vascular Disorders

      2011, MacSween's Pathology of the Liver: Expert Consult: Online and Print
    View all citing articles on Scopus
    1

    From the Section of Rheumatology, Department of Medicine, West Virginia University School of Medicine, Morgantown, WV.

    2

    From the Section of Comprehensive Medicine, Department of Medicine, West Virginia University School of Medicine, Morgantown, WV.

    3

    From the Section of Gastroenterology, Department of Medicine, West Virginia University School of Medicine, Morgantown, WV.

    4

    From the Department of Pathology, West Virginia University School of Medicine, Morgantown, WV.

    View full text